
  
    
      
        Introduction_NNP
        Rheumatoid_NNP arthritis_NN is_VBZ a_DT chronic_JJ debilitating_JJ
        autoimmune_JJ disease_NN of_IN unknown_JJ etiology_NN ._. Although_IN the_DT
        disease_NN is_VBZ characterized_VBN by_IN synovitis_NNS of_IN the_DT joints_NNS ,_, tendon_NN
        sheaths_NNS ,_, and_CC bursae_NN ,_, manifestations_NNS that_WDT do_VBP not_RB involve_VB the_DT
        synovium_NN are_VBP not_RB infrequent_JJ [_NN 1_CD ]_NN ._. These_DT articular_NN and_CC
        systemic_JJ manifestations_NNS appear_VBP to_TO be_VB mediated_JJ by_IN
        immunologic_JJ processes_VBZ [_NN 2_CD ]_NN ._. The_DT hallmarks_NNS of_IN the_DT synovial_NN
        abnormalities_NNS in_IN rheumatoid_NN arthritis_NN are_VBP synovial_NN lining_VBG
        cell_NN proliferation_NN ,_, neoangiogenesis_NNS ,_, and_CC inflammatory_JJ cell_NN
        infiltration_NN involving_VBG the_DT myeloid_NN ,_, macrophage_NN ,_, and_CC
        lymphoid_NN lineages_NNS [_NN 1_CD ,_, 2_CD ]_NN ._. There_EX has_VBZ been_VBN considerable_JJ
        controversy_NN regarding_VBG the_DT relative_JJ importance_NN of_IN the_DT types_NNS
        of_IN cells_NNS and_CC their_PRP$ products_NNS involved_VBN in_IN the_DT inflammatory_JJ
        processes_NNS of_IN rheumatoid_NN arthritis_NN [_NN 3_CD ]_NN ._. Nevertheless_RB ,_, it_PRP
        seems_VBZ likely_JJ that_IN all_DT of_IN these_DT cell_NN types_NNS participate_VBP to_TO
        some_DT degree_NN in_IN disease_NN pathogenesis_NNS ._.
        Evidence_NN in_IN support_NN of_IN T-_NNP cell_NN involvement_NN in_IN rheumatoid_NN
        arthritis_NN involves_VBZ the_DT description_NN of_IN restricted_VBN subsets_NNS of_IN
        T_NN cells_NNS in_IN the_DT blood_NN and_CC synovial_NN tissue_NN that_IN either_DT
        express_VB or_CC lack_NN certain_JJ surface_NN membrane_NN proteins_NNS or_CC that_WDT
        express_VBP a_DT limited_JJ set_NN of_IN antigen_NN receptors_NNS ._. For_IN example_NN ,_,
        clonal_NN amplifications_NNS of_IN CD_NNP 8_CD +_NN CD_NNP 57_CD +_NN T_NN cells_NNS are_VBP frequently_RB
        found_VBN in_IN the_DT T-_NNP cell_NN repertoire_NN of_IN rheumatoid_NN arthritis_NN
        patients_NNS [_NN 4_CD ]_NN ._. Furthermore_RB ,_, expanded_VBN clones_NNS of_IN CD_NNP 4_CD +_NN CD_NNP 28_CD -_: T_NN
        cells_NNS exist_VBP in_IN the_DT blood_NN and_CC synovial_NN compartments_NNS of_IN such_JJ
        patients_NNS [_NN 5_CD ]_NN and_CC these_DT T_NN cells_NNS appear_VBP to_TO be_VB autoreactive_JJ [_NN
        6_CD ]_NN ._. Finally_RB ,_, the_DT T-_NNP cell_NN receptors_NNS for_IN antigen_NN expressed_VBN by_IN
        these_DT and_CC other_JJ T-_NNP cell_NN subsets_NNS frequently_RB display_VBP a_DT bias_NN in_IN
        favor_NN of_IN receptors_NNS utilizing_VBG certain_JJ Vβ_NNP genes_NNS [_NN 5_CD ,_, 7_CD ,_, 8_CD ,_, 9_CD ,_,
        10_CD ,_, 11_CD ,_, 12_CD ]_NN ._.
        In_IN contrast_NN to_TO the_DT extensive_JJ studies_NNS of_IN the_DT clonal_NN
        distribution_NN of_IN T_NN cells_NNS in_IN rheumatoid_NN arthritis_NN ,_, much_RB less_JJR
        is_VBZ known_VBN about_IN the_DT level_NN of_IN B-_NNP cell_NN diversity_NN in_IN this_DT
        disease_NN ._. Previous_JJ studies_NNS ,_, however_RB ,_, are_VBP consistent_JJ with_IN the_DT
        interpretation_NN that_IN the_DT B-_NNP cell_NN repertoire_NN is_VBZ also_RB
        restricted_VBN ._. For_IN example_NN ,_, flow_NN cytometric_JJ analyses_NNS of_IN
        circulating_VBG B_NNP cells_NNS [_NN 13_CD ]_NN suggested_VBD that_DT oligoclonality_NN
        exists_VBZ ,_, and_CC cell_NN culture_NN experiments_NNS [_NN 14_CD ,_, 15_CD ,_, 16_CD ,_, 17_CD ]_NN
        demonstrated_VBN that_DT synovial_NN tissue_NN explants_NNS spontaneously_RB
        secrete_NN immunoglobulins_NNS of_IN restricted_VBN heterogeneity_NN as_IN
        defined_VBN by_IN immunoglobulin_NN (_( Ig_NNP )_) G_NNP subclass_NNS ,_, isoelectric_JJ
        focusing_VBG ,_, and_CC idiotype_NN expression_NN ._. More_RBR recent_JJ molecular_JJ
        analyses_NNS of_IN the_DT immunoglobulin_NN genes_NNS expressed_VBN by_IN B_NNP cells_NNS
        in_IN the_DT synovial_NN tissue_NN of_IN rheumatoid_NN arthritis_NN patients_NNS
        support_VBP these_DT notions_NNS [_NN 18_CD ,_, 19_CD ,_, 20_CD ,_, 21_CD ,_, 22_CD ]_NN ._.
        These_DT findings_NNS are_VBP important_JJ because_IN they_PRP suggest_VBP that_IN ,_,
        at_IN the_DT B-_NNP and_CC T-_NNP cell_NN levels_NNS ,_, an_DT ongoing_JJ immune_JJ reaction_NN is_VBZ
        occurring_VBG that_WDT is_VBZ directed_VBN at_IN restricted_VBN sets_NNS of_IN
        (_( auto_NN )_) antigens_NNS ._. The_DT present_JJ study_NN was_VBD designed_VBN to_TO analyze_VB
        further_VB the_DT level_NN of_IN clonal_NN diversity_NN in_IN rheumatoid_NN
        arthritis_NN B_NNP cells_NNS by_IN using_VBG the_DT length_NN of_IN the_DT third_JJ
        complementarity_NN determining_VBG region_NN (_( CDR_NNP 3_LS )_) of_IN the_DT rearranged_JJ
        heavy_JJ (_( H_NNP )_) chain_NN variable_JJ region_NN (_( V_NNP )_) gene_NN as_IN a_DT marker_NN
        (_( herein_NN referred_VBD to_TO as_IN HCDR_NNP 3_LS )_) ._. A_DT modification_NN of_IN the_DT
        immunoglobulin_NN V_NNP 
        H_NNP gene_NN fingerprinting_VBG method_NN [_NN 23_CD ]_NN that_WDT
        has_VBZ been_VBN used_VBN to_TO analyze_VB the_DT diversity_NN of_IN B_NNP cells_NNS and_CC T_NN
        cells_NNS in_IN several_JJ clinical_JJ settings_NNS [_NN 4_CD ,_, 24_CD ,_, 25_CD ,_, 26_CD ]_NN was_VBD
        used_VBN to_TO address_VB this_DT issue_NN ._. The_DT present_JJ data_NN suggest_VBP that_IN
        B-_NNP cell_NN clonal_NN expansion_NN is_VBZ a_DT common_JJ and_CC characteristic_JJ
        feature_NN of_IN rheumatoid_NN arthritis_NN ,_, that_IN it_PRP involves_VBZ both_DT
        resting_VBG and_CC activated_VBN cells_NNS ,_, and_CC that_IN it_PRP can_MD persist_VB over_IN
        extended_VBN periods_NNS of_IN time_NN ._. These_DT findings_NNS support_VBP the_DT idea_NN
        that_IN a_DT chronic_JJ (_( auto_NN )_) immune_JJ reaction_NN is_VBZ operative_JJ in_IN
        rheumatoid_NN arthritis_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Patients_NNS and_CC patient_NN samples_NNS
          Heparinized_NNP venous_JJ blood_NN ,_, synovial_NN fluid_JJ ,_, and_CC synovial_NN
          tissue_NN were_VBD obtained_VBN from_IN patients_NNS who_WP fulfilled_VBD the_DT
          American_NNP College_NNP of_IN Rheumatology_NNP criteria_NNS for_IN the_DT
          diagnosis_NN of_IN rheumatoid_NN arthritis_NN [_NN 27_CD ]_NN ._. Synovial_NNP tissue_NN
          removed_VBN at_IN the_DT time_NN of_IN either_DT joint_JJ replacement_NN or_CC
          therapeutic_JJ synovectomy_NN was_VBD digested_VBN with_IN collagenase_NN ,_,
          DNAse_NNP ,_, and_CC hyaluronidase_NN to_TO obtain_VB single-cell_JJ
          suspensions_NNS ._. Mononuclear_NNP cells_NNS (_( MNCs_NNP )_) were_VBD isolated_VBN from_IN
          cell_NN suspensions_NNS from_IN blood_NN ,_, synovial_NN fluid_JJ ,_, and_CC synovial_NN
          tissue_NN by_IN density_NN gradient_NN centrifugation_NN (_( Ficoll-_NNP Paque_NNP ;_:
          Pharmacia_NNP LKB_NNP Biotechnology_NNP ,_, Piscataway_NNP ,_, NJ_NNP ,_, USA_NNP )_) ._.
        
        
          Isolation_NNP of_IN DNA_NNP and_CC RNA_NNP ,_, and_CC preparation_NN of_IN
          complementary_JJ DNA_NNP
          Genomic_NNP DNA_NNP was_VBD isolated_VBN from_IN MNCs_NNP using_VBG the_DT Puregene_NNP
          DNA_NNP Isolation_NNP Kit_NNP (_( Gentra_NNP Systems_NNPS ,_, Mineapolis_NNP ,_, MN_NNP ,_, USA_NNP )_)
          and_CC total_JJ RNA_NNP was_VBD isolated_VBN using_VBG Ultraspec_NNP RNA_NNP (_( Biotech_NNP
          Laboratories_NNPS ,_, Houston_NNP ,_, TX_NNP ,_, USA_NNP )_) ._. Both_DT of_IN these_DT reagents_NNS
          were_VBD used_VBN according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._.
          One_CD microgram_NN of_IN RNA_NNP was_VBD reverse_VB transcribed_JJ to_TO
          complementary_JJ (_( c_SYM )_) DNA_NNP using_VBG 200_CD U_NNP Moloney_NNP murine_NN leukemia_NN
          virua_NN (_( M-MLV_NNP )_) reverse_VB transcriptase_NN (_( GIBCO_NNP BRL_NNP Life_NNP
          Technologies_NNPS ,_, Grand_NNP Island_NNP ,_, NY_NNP ,_, USA_NNP )_) ,_, 1_CD U_NNP RNAse_NNP inhibitor_NN
          (_( 5_CD Prime_NNP 3_CD Prime_NNP ,_, Boulder_NNP ,_, CO_NNP ,_, USA_NNP )_) and_CC 20_CD pmol_NN oligo_NN dT_NN
          primer_NN in_IN a_DT total_JJ volume_NN of_IN 20_CD μl_NN ._. These_DT ingredients_NNS were_VBD
          incubated_JJ at_IN 42_CD °_NN C_NNP for_IN 1_CD h_NN ,_, heated_VBN to_TO 65_CD °_NN C_NNP for_IN 10_CD min_NN to_TO
          stop_VB the_DT reactions_NNS ,_, and_CC then_RB diluted_VBN to_TO a_DT final_JJ volume_NN of_IN
          100_CD μl_NN ._.
        
        
          Polymerase_NNP chain_NN reaction_NN conditions_NNS for_IN
          immunoglobulin_NN V_NNP Hgene_NNP fingerprinting_VBG assay_NN
          
            Stage_NN I_PRP
            Genomic_NNP DNA_NNP (_( 100_CD ng_NN )_) was_VBD amplified_VBN using_VBG a_DT sense_NN V_NNP 
            H_NNP family-specific_JJ framework_NN region_NN
            (_( FR_NNP )_) 1_CD primer_NN in_IN conjunction_NN with_IN an_DT antisense_NN J_NNP 
            H_NNP consensus_NN primer_NN ._. These_DT reactions_NNS
            were_VBD carried_VBN out_IN in_IN 50_CD μ_NN l_NN using_VBG 5_CD pmol_NN of_IN each_DT primer_NN ,_,
            and_CC were_VBD cycled_JJ with_IN a_DT 9600_CD GeneAmp_NNP System_NNP (_( Perkin_NNP
            Elmer_NNP ,_, Emeryville_NNP ,_, CA_NNP ,_, USA_NNP )_) as_IN follows_VBZ :_: denaturation_NN at_IN
            94_CD °_NN C_NNP for_IN 40_CD s_VBZ ;_: annealing_VBG at_IN 65_CD °_NN C_NNP for_IN 45_CD s_VBZ ;_: and_CC
            extension_NN at_IN 72_CD °_NN C_NNP for_IN 40_CD s_VBZ ._. After_IN 35_CD cycles_NNS ,_, extension_NN
            was_VBD continued_VBN at_IN 72_CD °_NN C_NNP for_IN an_DT additional_JJ 10_CD min_NN ._.
            cDNA_NN (_( 2_CD μl_NN )_) was_VBD amplified_VBN using_VBG a_DT sense_NN V_NNP 
            H_NNP family-specific_JJ FR_NNP 1_CD primer_NN in_IN
            conjunction_NN with_IN the_DT appropriate_JJ antisense_NN C_NNP 
            H_NNP primer_NN ._. The_DT reactions_NNS were_VBD carried_VBN
            out_IN in_IN 50_CD μl_NN using_VBG 5_CD pmol_NN of_IN each_DT primer_NN and_CC cycled_JJ as_IN
            follows_VBZ :_: denaturation_NN at_IN 94_CD °_NN C_NNP for_IN 45_CD s_VBZ ;_: annealing_VBG at_IN
            65_CD °_NN C_NNP for_IN 45_CD s_VBZ ;_: and_CC extension_NN at_IN 72_CD °_NN C_NNP for_IN 45_CD s_VBZ ._. After_IN 35_CD
            cycles_NNS ,_, extension_NN was_VBD continued_VBN at_IN 72_CD °_NN C_NNP for_IN an_DT
            additional_JJ 10_CD min_NN ._.
          
          
            Stage_NNP II_NNP
            Polymerase_NNP chain_NN reaction_NN (_( PCR_NNP )_) products_NNS (_( 2_CD μ_NN l_NN )_)
            generated_VBN from_IN either_DT genomic_JJ DNA_NNP or_CC cDNA_NN were_VBD
            amplified_VBN using_VBG 5_CD pmol_NN of_IN nested_JJ sense_NN V_NNP 
            H_NNP family-specific_JJ FR_NNP 3_CD primer_NN and_CC
            radiolabeled_JJ antisense_NN nested_JJ J_NNP 
            H_NNP consensus_NN primer_NN that_WDT had_VBD been_VBN
            end-labeled_JJ with_IN γ_NN 32_CD -_: P_NN (_( New_NNP England_NNP Nuclear_NNP ,_, Beverly_NNP ,_,
            MA_NNP ,_, USA_NNP )_) using_VBG T_NN 4_CD polynucleotide_NN kinase_NN (_( Promega_NNP ,_,
            Madison_NNP ,_, WI_NNP ,_, USA_NNP )_) ._. The_DT reactions_NNS were_VBD carried_VBN out_IN in_IN 25_CD
            μ_NN l_NN and_CC cycled_JJ as_IN follows_VBZ :_: denaturation_NN at_IN 94_CD °_NN C_NNP for_IN 30_CD
            s_VBZ ;_: annealing_VBG at_IN 52_CD °_NN C_NNP for_IN 45_CD s_VBZ ;_: and_CC extension_NN at_IN 72_CD °_NN C_NNP
            for_IN 30_CD s_VBZ ._. After_IN 15_CD cycles_NNS ,_, extension_NN was_VBD continued_VBN at_IN
            72_CD °_NN C_NNP for_IN an_DT additional_JJ 10_CD min_NN ._. The_DT radiolabeled_JJ PCR_NNP
            products_NNS that_WDT reflected_VBD the_DT HCDR_NNP 3_CD lengths_NNS of_IN various_JJ
            B-_NNP cell_NN clones_NNS in_IN the_DT cell_NN suspension_NN were_VBD
            electrophoresed_JJ through_IN a_DT 6_CD %_NN denaturing_VBG acrylamide_NN
            sequencing_VBG gel_NN for_IN approximately_RB 1_CD ._. 5_CD h_NN ._. The_DT gel_NN was_VBD
            then_RB dried_VBN and_CC exposed_VBN to_TO film_NN overnight_JJ ._.
          
        
        
          DNA_NNP cloning_VBG and_CC sequencing_VBG
          DNA_NN sequences_NNS were_VBD determined_VBN by_IN reamplifying_VBG the_DT
          original_JJ genomic_JJ DNA_NNP using_VBG the_DT appropriate_JJ
          family-specific_JJ V_NNP 
          H_NNP leader_NN and_CC J_NNP 
          H_NNP consensus_NN primers_NNS under_IN the_DT
          following_VBG PCR_NNP conditions_NNS :_: denaturation_NN at_IN 94_CD °_NN C_NNP for_IN 45_CD s_VBZ ;_:
          annealing_VBG at_IN 62_CD °_NN C_NNP for_IN 30_CD s_VBZ ;_: and_CC extension_NN at_IN 72_CD °_NN C_NNP for_IN 45_CD s_VBZ ._.
          After_IN 35_CD cycles_NNS ,_, extension_NN was_VBD continued_VBN at_IN 72_CD °_NN C_NNP for_IN an_DT
          additional_JJ 10_CD min_NN ._. PCR_NNP products_NNS were_VBD then_RB cloned_VBN into_IN TA_NNP
          vector_NN (_( Invitrogen_NNP ,_, San_NNP Diego_NNP ,_, CA_NNP ,_, USA_NNP )_) ,_, processed_VBN using_VBG
          Wizard_NNP minipreps_NNS (_( Promega_NNP )_) ,_, and_CC sequenced_JJ using_VBG M_NNP 13_CD
          forward_RB and_CC reverse_VB primers_NNS ,_, a_DT DNA_NNP Sequencing_NNP Kit_NNP (_( Perkin_NNP
          Elmer_NNP )_) and_CC an_DT automated_VBN sequenator_NN (_( Applied_NNP Biosystems_NNP ,_,
          Foster_NNP City_NNP ,_, CA_NNP ,_, USA_NNP )_) ._.
        
      
      
        Results_NNS and_CC discussion_NN
        
          Identification_NNP of_IN B-_NNP cell_NN clonal_NN expansions_NNS using_VBG a_DT
          modified_VBN immunoglobulin_NN V_NNP Hgene_NNP fingerprinting_VBG
          assay_NN
          During_IN normal_JJ B_NNP cell_NN development_NN ,_, the_DT processes_NNS of_IN
          gene_NN segment_NN recombination_NN and_CC coding_VBG end_NN processing_NN
          yield_NN nucleotide_NN HCDR_NNP 3_CD lengths_NNS that_WDT are_VBP characteristic_JJ
          and_CC virtually_RB invariant_NN for_IN an_DT individual_JJ B-_NNP cell_NN clone_NN ._.
          Therefore_RB ,_, these_DT lengths_NNS can_MD be_VB used_VBN as_IN signatures_NNS to_TO
          identify_VB members_NNS of_IN a_DT B_NNP cell_NN clone_NN ._. The_DT immunoglobulin_NN V_NNP 
          H_NNP gene_NN fingerprinting_VBG approach_NN [_NN 23_CD ]_NN
          takes_VBZ advantage_NN of_IN the_DT wide_JJ range_NN of_IN HCDR_NNP 3_CD lengths_NNS that_WDT
          can_MD occur_VB in_IN human_JJ B_NNP cells_NNS (_( approximately_RB 5_CD -_: 35_CD amino_JJ
          acids_NNS )_) to_TO provide_VB an_DT estimate_NN of_IN clonal_NN diversity_NN in_IN
          polyclonal_NN populations_NNS ._. When_WRB polyclonal_NN B_NNP lymphocytes_NNS
          from_IN adults_NNS are_VBP analyzed_VBN using_VBG this_DT assay_NN ,_, they_PRP display_VBP a_DT
          Gaussian_NNP HCDR_NNP 3_CD length_NN distribution_NN around_IN a_DT mean_NN of_IN
          approximately_RB 15_CD amino_JJ acids_NNS ._. The_DT presence_NN of_IN an_DT
          individual_JJ dominant_JJ length_NN that_WDT differs_VBZ from_IN this_DT
          Gaussian_NNP distribution_NN can_MD be_VB used_VBN as_IN an_DT indication_NN of_IN a_DT
          specific_JJ B-_NNP cell_NN clonal_NN expansion_NN ._.
          Figure_NN 1_CD illustrates_VBZ schematically_RB the_DT two-stage_JJ
          immunoglobulin_NN V_NNP 
          H_NNP gene_NN fingerprinting_VBG approach_NN that_IN we_PRP
          utilized_JJ ._. Note_VB that_IN when_WRB cDNA_NN prepared_VBN from_IN normal_JJ
          peripheral_JJ blood_NN B_NNP cells_NNS is_VBZ used_VBN as_IN a_DT template_NN for_IN these_DT
          V_NNP 
          H_NNP family-specific_JJ and_CC C_NNP 
          H_NNP -_: specific_JJ assays_NNS ,_, ladders_NNS of_IN HCDR_NNP 3_CD
          lengths_NNS that_WDT differ_VBP by_IN three_CD nucleotides_NNS are_VBP identified_VBN ._.
          These_DT individual_JJ HCDR_NNP 3_CD lengths_NNS are_VBP signatures_NNS of_IN the_DT
          various_JJ individual_JJ B-_NNP cell_NN clones_NNS contained_VBD within_IN the_DT
          polyclonal_NN population_NN ._. The_DT intensities_NNS of_IN the_DT bands_NNS in_IN
          virtually_RB all_DT of_IN the_DT ladders_NNS illustrated_VBN in_IN Figure_NN 1_CD are_VBP
          relatively_RB uniformly_RB distributed_VBN around_IN the_DT mean_NN ._. This_DT
          indicates_VBZ that_IN there_EX are_VBP no_DT dominant_JJ HCDR_NNP 3_CD lengths_NNS that_WDT
          skew_NN the_DT Gaussian_NNP distribution_NN ,_, and_CC therefore_RB that_IN there_EX
          are_VBP no_DT significant_JJ clonal_NN expansions_NNS among_IN the_DT B_NNP cells_NNS
          that_WDT express_VBP most_JJS of_IN these_DT V_NNP 
          H_NNP -_: C_NNP 
          H_NNP combinations_NNS ._. Similar_JJ results_NNS are_VBP
          obtained_VBN using_VBG the_DT genomic_JJ DNA-based_NNP assay_NN ,_, although_IN
          these_DT results_NNS cannot_NN be_VB interpreted_VBN in_IN a_DT C_NNP 
          H_NNP -_: specific_JJ manner_NN (_( data_NNS not_RB
          shown_VBN )_) ._.
          In_IN the_DT V_NNP 
          H_NNP 6_CD -_: IgG_NNP combination_NN (_( Fig_NNP ._. 1_LS )_) ,_, however_RB ,_,
          a_DT non-_NN Gaussian_NNP distribution_NN is_VBZ noted_VBN ,_, even_RB in_IN this_DT normal_JJ
          individual_NN ._. This_DT could_MD be_VB a_DT reflection_NN of_IN the_DT numbers_NNS of_IN
          V_NNP 
          H_NNP genes_NNS present_JJ in_IN the_DT V_NNP 
          H_NNP family_NN being_VBG analyzed_VBN (_( it_PRP is_VBZ more_RBR
          likely_JJ to_TO see_VB a_DT non-_NN Gaussian_NNP distribution_NN in_IN families_NNS
          with_IN small_JJ numbers_NNS of_IN individual_JJ genes_NNS )_) or_CC of_IN the_DT state_NN
          of_IN activation_NN of_IN a_DT specific_JJ clone_NN (_( because_IN activated_VBN B_NNP
          cells_NNS contain_VBP much_RB higher_JJR levels_NNS of_IN V_NNP gene_NN messenger_NN RNA_NNP
          than_IN resting_VBG B_NNP cells_NNS )_) ._. We_PRP believe_VBP that_IN in_IN the_DT instance_NN
          illustrated_VBN in_IN Figure_NN 1_CD the_DT latter_JJ possibility_NN is_VBZ more_RBR
          likely_JJ ,_, because_IN the_DT small_JJ V_NNP 
          H_NNP 2_CD and_CC V_NNP 
          H_NNP 5_CD families_NNS (_( only_RB two_CD gene_NN members_NNS
          per_IN family_NN )_) do_VBP not_RB exhibit_VB the_DT same_JJ degree_NN of_IN
          oligoclonality_NN as_IN that_DT observed_VBD with_IN the_DT only_RB somewhat_RB
          smaller_JJR V_NNP 
          H_NNP 6_CD family_NN (_( one_CD gene_NN member_NN )_) ._.
        
        
          Distinction_NNP between_IN clonal_NN expansion_NN and_CC clonal_NN
          activation_NN using_VBG the_DT modified_VBN immunoglobulin_NN V_NNP Hgene_NNP
          fingerprinting_VBG assay_NN
          Because_IN B-_NNP cell_NN activation_NN and_CC differentiation_NN result_NN
          in_IN dramatic_JJ increases_NNS in_IN immunoglobulin_NN V_NNP gene_NN messenger_NN
          RNA_NNP ,_, these_DT fingerprinting_VBG assays_NNS cannot_NN readily_RB
          distinguish_VB between_IN clonal_NN expansion_NN and_CC activation_NN when_WRB
          cDNA_NN is_VBZ used_VBN as_IN a_DT starting_VBG template_NN ._. Because_IN DNA_NNP levels_NNS
          are_VBP not_RB appreciably_RB altered_VBN by_IN cellular_JJ activation_NN ,_,
          however_RB ,_, the_DT use_NN of_IN genomic_JJ DNA_NNP as_RB well_RB as_IN cDNA_NN from_IN the_DT
          same_JJ sample_NN of_IN B_NNP cells_NNS helps_VBZ to_TO distinguish_VB these_DT two_CD
          processes_NNS ._.
          Thus_RB ,_, in_IN the_DT setting_NN of_IN specific_JJ B-_NNP cell_NN clonal_NN
          expansion_NN without_IN concomitant_NN cellular_JJ activation_NN ,_, the_DT
          DNA-based_NNP fingerprinting_VBG assay_NN will_MD indicate_VB a_DT dominant_JJ
          HCDR_NNP 3_CD length_NN ,_, whereas_IN the_DT cDNA-based_JJ assay_NN may_MD not_RB (_( data_NNS
          not_RB shown_VBN )_) ._. Conversely_RB ,_, in_IN the_DT setting_NN of_IN specific_JJ B-_NNP cell_NN
          clonal_NN activation_NN without_IN concomitant_NN clonal_NN expansion_NN ,_,
          the_DT cDNA-based_JJ assay_NN will_MD indicate_VB a_DT dominant_JJ HCDR_NNP 3_CD
          length_NN ,_, whereas_IN the_DT DNA-based_NNP assay_NN may_MD not_RB ._. Finally_RB ,_, in_IN
          the_DT setting_NN of_IN specific_JJ B-_NNP cell_NN clonal_NN activation_NN with_IN
          concomitant_NN clonal_NN expansion_NN ,_, both_DT the_DT cDNA-_NN and_CC the_DT
          DNA-based_NNP assays_NNS will_MD indicate_VB a_DT dominant_JJ HCDR_NNP 3_CD
          length_NN ._.
          These_DT distinctions_NNS were_VBD very_RB reproducible_JJ in_IN the_DT
          following_VBG studies_NNS ._. There_EX were_VBD no_DT situations_NNS in_IN which_WDT
          evidence_NN for_IN cellular_JJ activation_NN (_( either_CC selective_JJ or_CC
          accompanied_VBN by_IN clonal_NN expansion_NN )_) was_VBD present_JJ in_IN one_CD set_NN
          of_IN analyses_NNS and_CC not_RB in_IN a_DT subsequent_JJ set_VBN using_VBG the_DT same_JJ
          starting_NN materials_NNS ._.
        
        
          B_NN cells_NNS in_IN the_DT blood_NN ,_, synovial_NN fluid_JJ ,_, and_CC synovial_NN
          tissue_NN of_IN rheumatoid_NN arthritis_NN patients_NNS exhibit_NN clonal_NN
          expansions_NNS of_IN activated_VBN and_CC resting_VBG B_NNP cells_NNS
          We_PRP analyzed_VBD the_DT peripheral_JJ blood_NN ,_, synovial_NN fluid_JJ ,_, and_CC
          synovial_NN tissue_NN B_NNP cells_NNS of_IN rheumatoid_NN arthritis_NN patients_NNS
          (_( 
          n_NN =_SYM 20_CD ,_, 10_CD ,_, and_CC 5_CD ,_, respectively_RB )_)
          using_VBG the_DT genomic_JJ DNA-_NNP and_CC cDNA-based_JJ fingerprinting_VBG
          assays_NNS to_TO develop_VB an_DT understanding_NN of_IN the_DT diversity_NN of_IN
          the_DT B_NNP cells_NNS in_IN these_DT compartments_NNS ._. Figures_NNS 2_CD and_CC 3_CD are_VBP
          illustrations_NNS of_IN representative_NN patients_NNS for_IN whom_WP
          concomitant_NN blood_NN and_CC synovial_NN fluid_NN or_CC blood_NN and_CC
          synovial_NN tissue_NN samples_NNS were_VBD available_JJ ._. In_IN order_NN to_TO
          simplify_VB the_DT Figures_NNS ,_, only_RB the_DT results_NNS for_IN two_CD large_JJ V_NNP 
          H_NNP families_NNS (_( V_NNP 
          H_NNP 1_CD and_CC V_NNP 
          H_NNP 3_LS )_) and_CC two_CD small_JJ V_NNP 
          H_NNP families_NNS (_( V_NNP 
          H_NNP 5_CD and_CC V_NNP 
          H_NNP 6_CD )_) are_VBP provided_VBN ,_, although_IN assays_NNS for_IN
          each_DT V_NNP 
          H_NNP family_NN and_CC each_DT major_JJ CH_NNP family_NN
          (_( μ_NN ,_, γ_NN ,_, and_CC α_NN )_) were_VBD performed_VBN and_CC revealed_VBN similar_JJ
          findings_NNS ._.
          The_DT genomic_JJ DNA-based_NNP assays_NNS in_IN both_DT patients_NNS
          indicated_VBD that_IN clonal_NN expansions_NNS are_VBP common_JJ in_IN the_DT blood_NN
          of_IN rheumatoid_NN arthritis_NN patients_NNS ._. This_DT type_NN of_IN result_NN was_VBD
          obtained_VBN with_IN all_DT individuals_NNS tested_VBN ._. It_PRP was_VBD most_RBS
          convincingly_RB demonstrated_VBN by_IN the_DT results_NNS in_IN Figure_NN
          3_CD obtained_VBN from_IN B_NNP cells_NNS expressing_VBG genes_NNS of_IN the_DT V_NNP 
          H_NNP 1_CD and_CC V_NNP 
          H_NNP 3_CD families_NNS ._. Because_IN these_DT V_NNP 
          H_NNP families_NNS contain_VBP the_DT largest_JJS numbers_NNS
          of_IN V_NNP 
          H_NNP genes_NNS ,_, they_PRP would_MD be_VB more_RBR likely_JJ to_TO
          display_VB a_DT polyclonal_NN pattern_NN ._.
          An_DT even_RB more_RBR striking_JJ level_NN of_IN B-_NNP cell_NN clonal_NN dominance_NN
          and_CC expansion_NN was_VBD seen_VBN when_WRB the_DT genomic_JJ DNA-based_NNP assay_NN
          was_VBD used_VBN to_TO analyze_VB B_NNP cells_NNS from_IN the_DT synovial_NN fluid_NN or_CC
          synovial_NN tissue_NN (_( Figs_NNP 2_CD and_CC 3_LS )_) ._. In_IN these_DT analyses_NNS ,_,
          virtually_RB all_DT V_NNP 
          H_NNP families_NNS demonstrated_VBD extensive_JJ
          B-_NNP cell_NN oligoclonality_NN ._. It_PRP should_MD be_VB pointed_VBN out_RP that_IN when_WRB
          an_DT individual_JJ HCDR_NNP 3_CD length_NN comprises_VBZ more_JJR than_IN 50_CD %_NN of_IN the_DT
          radioactive_JJ counts_NNS of_IN a_DT V_NNP 
          H_NNP -_: C_NNP 
          H_NNP ladder_NN ,_, clonality_NN ,_, based_VBN on_IN DNA_NNP
          sequencing_VBG ,_, is_VBZ very_RB likely_JJ ;_: when_WRB an_DT individual_JJ length_NN
          comprises_VBZ more_JJR than_IN 70_CD %_NN of_IN the_DT radioactivity_NN ,_, clonality_NN
          is_VBZ virtually_RB assured_VBN (_( data_NNS not_RB shown_VBN )_) ._.
          Collectively_RB ,_, these_DT data_NNS indicate_VBP that_IN the_DT B-_NNP cell_NN
          repertoire_NN of_IN rheumatoid_NN arthritis_NN patients_NNS is_VBZ skewed_VBN
          away_RB from_IN the_DT typical_JJ ,_, apparently_RB random_JJ representation_NN
          of_IN normal_JJ individuals_NNS ._. The_DT reason_NN for_IN this_DT discrepancy_NN is_VBZ
          not_RB clear_JJ ,_, although_IN one_CD possibility_NN is_VBZ that_WDT restricted_VBD
          antigenic_JJ exposure_NN alters_NNS the_DT composition_NN of_IN the_DT
          repertoire_NN in_IN favor_NN of_IN B_NNP cells_NNS reactive_JJ with_IN the_DT putative_JJ
          antigen_NN (_( s_VBZ )_) ._. If_IN this_DT is_VBZ so_RB ,_, the_DT progressive_JJ narrowing_NN of_IN
          the_DT repertoire_NN from_IN the_DT blood_NN to_TO the_DT synovial_NN tissue_NN is_VBZ
          consistent_JJ with_IN the_DT ideas_NNS that_IN the_DT antigenic_JJ exposures_NNS
          are_VBP originating_VBG at_IN these_DT sites_NNS and_CC that_IN the_DT synovial_NN
          compartment_NN is_VBZ supporting_VBG clonal_NN amplification_NN ._. Because_IN
          these_DT are_VBP true_JJ clonal_NN expansions_NNS (_( ie_NN increased_VBN numbers_NNS of_IN
          B_NNP cells_NNS per_IN specific_JJ clone_NN )_) ,_, it_PRP is_VBZ likely_JJ that_IN the_DT
          antigenic_JJ exposures_NNS are_VBP chronic_JJ and_CC therefore_RB are_VBP
          increasing_VBG the_DT numbers_NNS of_IN memory_NN B_NNP cells_NNS reactive_JJ with_IN
          these_DT determinants_NNS ._.
          In_IN order_NN to_TO confirm_VB that_IN these_DT clonally_RB expanded_VBN B_NNP
          cells_NNS were_VBD receiving_VBG ongoing_JJ antigenic_JJ stimulation_NN and_CC
          not_RB limited_JJ solely_RB to_TO the_DT memory_NN compartment_NN ,_, we_PRP employed_VBN
          the_DT cDNA-based_JJ assay_NN to_TO distinguish_VB clonal_NN expansions_NNS of_IN
          activated_VBN B_NNP cells_NNS from_IN resting_VBG (_( memory_NN )_) cells_NNS ._. As_IN
          illustrated_VBN in_IN Figure_NN 2_CD ,_, activated_VBN B-_NNP cell_NN clones_NNS
          (_( identified_VBN by_IN the_DT letter_NN '_'' A_NNP '_POS in_IN Fig_NNP ._. 2_LS )_) expressing_VBG each_DT
          of_IN the_DT immunoglobulin_NN heavy-chain_JJ isotypes_NNS were_VBD easily_RB
          identified_VBN in_IN all_PDT the_DT V_NNP 
          H_NNP families_NNS studied_VBN ._. In_IN some_DT instances_NNS ,_,
          these_DT activated_VBN clones_NNS were_VBD also_RB expanded_VBN numerically_RB (_( as_IN
          defined_VBN by_IN the_DT genomic_JJ DNA-based_NNP assays_NNS ,_, and_CC identified_VBN
          by_IN the_DT letter_NN '_'' E_NNP '_POS in_IN Fig_NNP ._. 2_LS )_) ._. In_IN other_JJ cases_NNS ,_, these_DT
          activated_VBN clones_NNS did_VBD not_RB appear_VB to_TO be_VB numerically_RB
          expanded_VBN ._. Similar_JJ examples_NNS can_MD be_VB found_VBN in_IN Figures_NNS 3_CD and_CC
          4_CD ,_, but_CC they_PRP are_VBP not_RB identified_VBN by_IN letters_NNS in_IN order_NN to_TO
          simplify_VB the_DT Figures_NNS ._.
          Thus_RB ,_, it_PRP appears_VBZ that_IN many_JJ discrete_JJ B-_NNP cell_NN clones_NNS
          exist_VBP in_IN the_DT synovial_NN compartment_NN of_IN rheumatoid_NN arthritis_NN
          patients_NNS ,_, and_CC that_IN these_DT are_VBP increased_VBN in_IN number_NN ,_,
          consistent_JJ with_IN a_DT response_NN to_TO a_DT restricted_VBN antigenic_JJ
          challenge_NN (_( s_VBZ )_) ._. Furthermore_RB ,_, these_DT B-_NNP cell_NN clones_NNS appear_VBP to_TO
          be_VB of_IN both_DT the_DT resting_VBG (_( memory_NN )_) and_CC the_DT activated_VBN types_NNS ,_,
          suggesting_VBG that_IN these_DT antigenic_JJ challenges_NNS are_VBP chronic_JJ
          and_CC ongoing_JJ ._. Thus_RB ,_, these_DT data_NNS support_VBP and_CC extend_VB previous_JJ
          findings_NNS [_NN 18_CD ,_, 19_CD ,_, 20_CD ,_, 21_CD ,_, 22_CD ]_NN by_IN indicating_VBG that_IN
          specific_JJ B-_NNP cell_NN clonal_NN amplifications_NNS can_MD occur_VB both_DT in_IN
          previously_RB stimulated_VBN B_NNP cells_NNS and_CC in_IN currently_RB activated_VBN
          B_NNP cells_NNS ._. The_DT presence_NN of_IN activated_VBN B_NNP cells_NNS that_WDT are_VBP not_RB
          increased_VBN in_IN number_NN is_VBZ consistent_JJ either_CC with_IN recent_JJ 
          in_IN situ_NN synovium-specific_JJ
          stimulation_NN of_IN these_DT B-_NNP cell_NN clones_NNS ,_, or_CC with_IN the_DT influx_NN of_IN
          activated_VBN B_NNP cells_NNS that_WDT were_VBD stimulated_VBN by_IN antigens_NNS
          outside_IN of_IN and_CC not_RB necessarily_RB relevant_JJ to_TO the_DT synovial_NN
          compartment_NN ._.
        
        
          B-_NNP cell_NN clonal_NN expansions_NNS in_IN the_DT blood_NN and_CC synovial_NN
          compartments_NNS can_MD be_VB restricted_VBN to_TO one_CD or_CC another_DT
          compartment_NN ,_, or_CC be_VB common_JJ to_TO the_DT two_CD
          Because_IN the_DT preceding_VBG data_NN indicated_VBD that_IN the_DT B-_NNP cell_NN
          repertoire_NN of_IN rheumatoid_NN arthritis_NN patients_NNS contains_VBZ
          expanded_VBN clones_NNS of_IN B_NNP cells_NNS that_WDT can_MD be_VB resting_VBG or_CC
          activated_VBN ,_, we_PRP investigated_VBD whether_IN the_DT same_JJ clones_NNS could_MD
          be_VB identified_VBN in_IN both_DT the_DT blood_NN and_CC synovial_NN
          compartments_NNS ._. Figures_NNS 2_CD and_CC 3_CD illustrate_VBP data_NNS that_WDT suggest_VBP
          that_IN there_EX are_VBP expanded_VBN clones_NNS that_WDT are_VBP blood_NN restricted_VBD ,_,
          joint_JJ restricted_VBN ,_, or_CC are_VBP common_JJ to_TO both_DT compartments_NNS ._.
          Examples_NNS of_IN blood-restricted_JJ clones_NNS are_VBP highlighted_VBN on_IN
          Figures_NNS 2_CD and_CC 3_CD with_IN the_DT ▶_NN symbol_NN ,_, those_DT that_WDT are_VBP
          joint-restricted_JJ with_IN the_DT ▷_NN symbol_NN ,_, and_CC those_DT that_WDT are_VBP
          common_JJ to_TO the_DT two_CD compartments_NNS with_IN the_DT ◆_NN symbol_NN ._. These_DT
          findings_NNS suggest_VBP that_IN there_EX may_MD be_VB a_DT degree_NN of_IN cellular_JJ
          trafficking_NN between_IN the_DT blood_NN and_CC the_DT synovial_NN
          tissues_NNS ._.
          In_IN order_NN to_TO address_VB this_DT issue_NN ,_, we_PRP studied_VBD the_DT B_NNP cells_NNS
          of_IN the_DT blood_NN and_CC two_CD synovial_NN sites_NNS (_( right_NN and_CC left_VBD hip_NN )_)
          that_WDT were_VBD obtained_VBN from_IN the_DT same_JJ patient_NN within_IN 3_CD h_NN of_IN
          each_DT other_JJ (_( Fig_NNP ._. 4_LS )_) ._. In_IN this_DT patient_NN ,_, the_DT DNA-based_NNP assay_NN
          provided_VBD examples_NNS of_IN clonal_NN expansions_NNS that_WDT were_VBD present_JJ
          in_IN only_RB one_CD joint_JJ (_( eg_NN the_DT V_NNP 
          H_NNP 3_CD -_: J_NNP 
          H_NNP and_CC V_NNP 
          H_NNP 5_CD -_: J_NNP 
          H_NNP combinations_NNS in_IN Figure_NN 4_LS )_) ,_, and_CC the_DT
          companion_NN cDNA-based_JJ assays_NNS indicated_VBD that_IN in_IN some_DT
          instances_NNS these_DT expansions_NNS were_VBD either_CC activated_VBN or_CC
          resting_VBG ._. In_IN only_RB rare_JJ instances_NNS ,_, however_RB ,_, did_VBD the_DT data_NNS
          suggest_VBP that_IN a_DT similar_JJ clone_NN was_VBD present_JJ in_IN two_CD different_JJ
          synovial_NN tissues_NNS ._. DNA_NN sequence_NN analyses_NNS confirmed_VBD the_DT
          rarity_NN of_IN this_DT event_NN (_( data_NNS not_RB shown_VBN )_) ._. Thus_RB it_PRP appears_VBZ
          that_IN in_IN most_JJS instances_NNS the_DT clonal_NN amplifications_NNS occur_VBP 
          in_IN situ_NN and_CC are_VBP not_RB the_DT result_NN of_IN
          trafficking_NN from_IN one_CD anatomic_JJ site_NN to_TO another_DT ._. If_IN so_RB ,_,
          this_DT would_MD suggest_VB that_IN the_DT antigenic_JJ challenges_NNS driving_VBG
          these_DT clonal_NN expansions_NNS may_MD not_RB be_VB common_JJ to_TO all_DT synovial_NN
          tissues_NNS ,_, but_CC may_MD be_VB generated_VBN independently_RB at_IN each_DT site_NN ,_,
          possibly_RB by_IN ongoing_JJ tissue_NN breakdown_NN ._.
        
        
          Clonal_NNP persistence_NN in_IN the_DT synovial_NN fluid_JJ
          compartment_NN
          If_IN the_DT clonal_NN expansions_NNS identified_VBN in_IN the_DT joints_NNS of_IN
          rheumatoid_NN arthritis_NN patients_NNS are_VBP due_JJ to_TO an_DT ongoing_JJ
          response_NN to_TO antigen_NN ,_, then_RB one_PRP would_MD predict_VB that_IN at_IN least_JJS
          some_DT of_IN the_DT clones_NNS would_MD persist_VB over_IN time_NN ._. To_TO test_VB this_DT ,_,
          we_PRP studied_VBD the_DT synovial_NN fluid_JJ B_NNP cells_NNS from_IN the_DT same_JJ
          joints_NNS of_IN three_CD patients_NNS on_IN two_CD occasions_NNS spanning_VBG
          several_JJ months_NNS ._. Most_JJS of_IN the_DT clonal_NN expansions_NNS detected_VBD on_IN
          the_DT initial_JJ samples_NNS were_VBD not_RB present_JJ in_IN the_DT subsequent_JJ
          samples_NNS ._. In_IN a_DT few_JJ instances_NNS ,_, however_RB ,_, B-_NNP cell_NN clonal_NN
          persistence_NN was_VBD found_VBN ._.
          Figure_NN 5_CD illustrates_VBZ the_DT best_JJS example_NN of_IN this_DT
          phenomenon_NN in_IN a_DT patient_NN who_WP was_VBD studied_VBN over_IN a_DT 4_CD -_: month_NN
          interval_NN ._. The_DT DNA-based_NNP assay_NN using_VBG V_NNP 
          H_NNP 4_CD family-specific_JJ primers_NNS indicated_VBD
          the_DT presence_NN of_IN two_CD similar_JJ clones_NNS on_IN days_NNS 0_CD and_CC 120_CD ,_,
          whereas_IN the_DT other_JJ V_NNP 
          H_NNP 4_CD -_: expressing_VBG clones_NNS detected_VBD at_IN the_DT
          first_JJ analysis_NN were_VBD no_DT longer_RB present_JJ at_IN the_DT time_NN of_IN the_DT
          second_JJ analysis_NN ._. DNA_NN sequence_NN analyses_NNS of_IN one_CD of_IN these_DT
          two_CD clones_NNS confirmed_VBD their_PRP$ identity_NN ,_, because_IN each_DT
          displayed_VBD the_DT same_JJ rearranged_JJ V_NNP 
          H_NNP DJ_NNP 
          H_NNP gene_NN with_IN identical_JJ V_NNP 
          H_NNP mutations_NNS and_CC identical_JJ HCDR_NNP 3_CD
          sequences_NNS (_( data_NNS not_RB shown_VBN )_) ._. Therefore_RB ,_, certain_JJ clones_NNS can_MD
          persist_VB locally_RB over_IN time_NN ,_, suggesting_VBG that_IN a_DT common_JJ and_CC
          persistent_JJ antigenic_JJ stimulation_NN was_VBD operable_JJ in_IN the_DT
          joint_NN of_IN this_DT rheumatoid_NN arthritis_NN patient_NN ._.
          The_DT lack_NN of_IN persistence_NN of_IN the_DT other_JJ B-_NNP cell_NN clones_NNS
          suggests_VBZ two_CD possibilities_NNS ._. First_LS ,_, the_DT initial_JJ set_NN of_IN
          B-_NNP cell_NN clones_NNS might_MD have_VB been_VBN replaced_VBN by_IN others_NNS that_WDT
          recognized_VBD and_CC responded_VBN to_TO different_JJ antigenic_JJ epitopes_NNS
          on_IN the_DT same_JJ original_JJ immunogenic_JJ protein_NN ._. This_DT type_NN of_IN
          clonal_NN evolution_NN to_TO the_DT recognition_NN of_IN different_JJ epitopes_NNS
          on_IN the_DT same_JJ immunogenic_JJ moiety_NN is_VBZ common_JJ in_IN experimental_JJ
          situations_NNS in_IN which_WDT repetitive_JJ immunizations_NNS with_IN a_DT
          defined_VBN antigen_NN are_VBP delivered_VBN [_NN 29_CD ,_, 30_CD ,_, 31_CD ]_NN ._. The_DT other_JJ
          possibility_NN is_VBZ that_IN the_DT B_NNP cells_NNS that_WDT disappeared_VBD over_IN
          time_NN were_VBD not_RB reactive_JJ with_IN tissue_NN antigens_NNS ._. These_DT could_MD
          have_VB been_VBN stimulated_VBN by_IN irrelevant_JJ antigens_NNS in_IN the_DT
          periphery_NN and_CC therefore_RB ,_, after_IN entering_VBG the_DT synovial_NN
          compartment_NN ,_, could_MD not_RB be_VB restimulated_JJ and_CC hence_RB could_MD
          not_RB enter_VB the_DT memory_NN pool_NN and_CC take_VB up_RB residence_NN in_IN the_DT
          synovial_NN tissue_NN ._.
        
      
      
        Conclusion_NNP
        The_DT present_JJ data_NN indicate_VBP that_DT clonal_NN expansion_NN is_VBZ a_DT
        common_JJ occurrence_NN in_IN the_DT B-_NNP cell_NN repertoire_NN of_IN rheumatoid_NN
        arthritis_NN patients_NNS ._. These_DT expansions_NNS involve_VBP both_DT resting_VBG
        memory_NN B_NNP cells_NNS and_CC activated_VBN B_NNP cells_NNS ,_, some_DT of_IN which_WDT are_VBP
        derived_VBN from_IN the_DT memory_NN B-_NNP cell_NN compartment_NN ._. Because_IN the_DT
        extent_NN of_IN these_DT clonal_NN expansions_NNS increases_NNS from_IN the_DT blood_NN
        to_TO the_DT synovial_NN compartment_NN ,_, this_DT progressive_JJ narrowing_NN in_IN
        diversity_NN implies_VBZ that_IN antigens_NNS located_VBN in_IN the_DT synovia_NN are_VBP
        responsible_JJ for_IN these_DT antigen-receptor_JJ biases_NNS ._. In_IN support_NN
        of_IN this_DT hypothesis_NNS are_VBP the_DT observations_NNS that_IN some_DT of_IN these_DT
        clonal_NN expansions_NNS are_VBP joint_JJ specific_NN ._. Because_IN identical_JJ
        clones_NNS are_VBP rarely_RB found_VBN in_IN two_CD different_JJ joints_NNS ,_, however_RB ,_,
        these_DT immune_JJ reactions_NNS are_VBP probably_RB unique_JJ to_TO each_DT
        individual_JJ joint_NN ._. Furthermore_RB ,_, because_IN it_PRP is_VBZ unlikely_JJ that_IN
        each_DT joint_JJ would_MD harbor_NN a_DT different_JJ foreign_JJ antigen_NN ,_, these_DT
        B_NNP cells_NNS are_VBP most_RBS likely_JJ reacting_VBG with_IN autoantigens_NNS
        generated_VBN locally_RB ,_, possibly_RB by_IN local_JJ tissue_NN breakdown_NN ._.
        Recent_JJ studies_NNS [_NN 20_CD ,_, 32_CD ]_NN have_VBP demonstrated_VBN that_IN the_DT
        synovial_NN tissue_NN of_IN rheumatoid_NN arthritis_NN patients_NNS can_MD
        develop_VB lymphoid_NN aggregates_NNS that_WDT have_VBP the_DT cellular_JJ
        components_NNS of_IN an_DT ectopic_JJ germinal_NN center_NN and_CC that_DT can_MD
        sustain_VB B-_NNP cell_NN clonal_NN expansion_NN and_CC diversification_NN ._. It_PRP is_VBZ
        likely_JJ that_IN the_DT B_NNP cells_NNS that_WDT mature_VBP in_IN these_DT
        '_POS pseudogerminal_NN centers_NNS '_POS and_CC those_DT that_IN we_PRP have_VBP identified_VBN
        in_IN the_DT present_JJ studies_NNS are_VBP responding_VBG to_TO specific_JJ
        (_( auto_NN )_) antigens_NNS ._. Therefore_RB ,_, the_DT identification_NN of_IN the_DT
        antigenic_JJ reactivities_NNS of_IN these_DT B_NNP cells_NNS ,_, and_CC in_IN particular_JJ
        those_DT B_NNP cells_NNS within_IN the_DT memory_NN compartment_NN that_WDT have_VBP
        presumably_RB traversed_JJ the_DT pseudogerminal_NN centers_NNS and_CC
        undergone_VBN (_( auto_NN )_) antigen_NN and_CC T_NN cell_NN selection_NN and_CC rescue_NN ,_,
        may_MD provide_VB important_JJ clues_NNS to_TO the_DT role_NN of_IN B_NNP lymphocytes_NNS
        and_CC their_PRP$ immunoglobulin_NN molecules_NNS in_IN the_DT
        immunopathogenesis_NNS of_IN rheumatoid_NN arthritis_NN ._.
      
    
  
